Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure

Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure

Abstract Background: A feedforward pathological signaling loop generated by TNFα and IFN-γ synergy in the inflamed lung, driving CXCL-10 (IP-10) and CXCL-9 chemokine-mediated activated T-cell and monocyte/macrophage tissue recruitment, may define the inflammatory biology of lethal COVID-19 respira...

Full description

Bibliographic Details
Main Authors: Hilal Hachem, Amandeep Godara, Courtney Schroeder, Daniel Fein, Hashim Mann, Christian Lawlor, Jill Marshall, Andreas Klein, Debra Poutsiaka, Janis L. Breeze, Raghav Joshi, Paul Mathew
Format: Article
Language:English
Published: Cambridge University Press 2021-01-01
Series:Journal of Clinical and Translational Science
Subjects:
TNFα
COVID-19
respiratory failure
infliximababda
CXCL-10
IP-10
Online Access:https://www.cambridge.org/core/product/identifier/S2059866121008050/type/journal_article

Internet

https://www.cambridge.org/core/product/identifier/S2059866121008050/type/journal_article

Similar Items